A Phase I/IIa study evaluating anti-CD19 CAR T-cell therapy after low-dose chemotherapy in people with advanced lymphoma

Trial Profile

A Phase I/IIa study evaluating anti-CD19 CAR T-cell therapy after low-dose chemotherapy in people with advanced lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2016 According to a Kite Pharma media release, data from this study will be presented at 2016 American Society Hematology Annual Meeting
    • 14 Jun 2016 New trial record
    • 08 Jun 2016 Data from this trial will be presented at the 2016 European Hematology Association (EHA) Annual Congress, according to a Kite Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top